Zura Bio Limited ZURA NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score

60/100

3/6 Pass

SharesGrow Intrinsic Value

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Zura Bio Limited (ZURA) generated $-64.82M in operating cash flow for fiscal year 2025. After capital expenditures of $113K, free cash flow was $-64.93M.

Cash conversion ratio was 0.94x, suggesting some earnings are non-cash.

Criteria supported by this page:

HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
MOAT (28/100, Fail) — limited free cash flow weakens the competitive position
INCOME (?/100) — Cash conversion ratio was 0.94x suggests some earnings are non-cash items

Overall SharesGrow Score: 59/100 with 3/7 criteria passed.

SharesGrow 7-Criteria Score

60/100

SG Score

View full scorecard →

✓

VALUE

100/100

Price-to-Earnings & upside

→ Valuation

✓

FUTURE

94/100

Analyst consensus

→ Forecast

✗

PAST

25/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

Proven by this page

✗

MOAT

28/100

Proven by this page

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

Zura Bio Limited Cash Flow History

Metric	TTM	FY2025	FY2024	FY2023	FY2022
Operating Cash Flow	$-64.82M	$-64.82M	$-28.08M	$-15.05M	$-1.07M
Capital Expenditure	$-113K	$-113K	$-75K	$-8M	$-12M
Free Cash Flow	$-64.93M	$-64.93M	$-28.15M	$-23.05M	$-13.07M